<DOC>
	<DOCNO>NCT00671697</DOCNO>
	<brief_summary>This study design test combination decitabine , arsenic trioxide ascorbic acid patient myelodysplastic syndrome ( MDS ) acute myeloid leukemia</brief_summary>
	<brief_title>Decitabine , Arsenic Trioxide Ascorbic Acid Myelodysplastic Syndromes Acute Myeloid Leukemia</brief_title>
	<detailed_description>Myelodysplastic syndrome ( MDS ) hematological disorder characterize ineffective hematopoiesis . DNA hypomethylating agent decitabine show activity disorder reverse epigenetic mechanism gene silence . Acute Myeloid Leukemia ( AML ) hematological disorder characterize ineffective hematopoiesis malignant expansion clonal myeloid cell . In elderly patient ( ≥ 60 year old ) , MDS commonly precede diagnosis AML . Standard therapy AML consist cytotoxic chemotherapy often follow allogeneic stem cell transplantation . Unfortunately , elderly patient often unable tolerate aggressive therapy . Arsenic also show activity patient MDS AML though modulation apoptosis via increase oxidative stress . In preclinical mode , arsenic activity relate production radical oxygen specie damage mitochondrion . Cellular glutathione act cellular antioxidant deplete vitamin ascorbic acid increase intracellular oxidative stress sensitivity arsenic trioxide induce apoptosis . We study combination decitabine , arsenic trioxide ascorbic acid , two primary agent one vitamin different mechanism action order improve response rate patient MDS AML . This open-label , single-arm , single-center , dose escalation Phase I trial decitabine , arsenic trioxide ascorbic acid patient MDS , either de novo secondary , fit FAB classification AML .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . MDS ( either de novo secondary ) fit FAB classification AML define FAB classification criterion . Patients &lt; 5 % bone marrow blast must also meet one follow criterion : 1 . Symptomatic anemia either hemoglobin &lt; 10.0 g/dL require red blood cell ( RBC ) transfusion 2 . Thrombocytopenia history two platelet count &lt; 50,000 / µL significant hemorrhage require platelet transfusion , 3 . Neutropenia two absolute neutrophil count &lt; 1,000 /µL . AML patient must also WBC &lt; 10,000µL meet one follow two criterion : 1 . Age great equal 60 year 2 . Relapsed AML candidate cytotoxic chemotherapy . 2 . ECOG performance status 02 . 3 . Must give write informed consent indicate awareness investigational nature study potential hazard . 4 . Adequate renal hepatic function ( creatinine &lt; 1.5x institutional upper limit normal , total bilirubin ≤ 1.5x institutional upper limit normal , AST ALT ≤ 2x institutional upper limit normal ) . 5 . Serum potassium &gt; 4.0 mEq/L , serum magnesium &gt; 1.8 mg/dL . 6 . Life expectancy least 16 week . 7 . Women childbearing age must negative serum pregnancy test prior initiate therapy . 8 . Sexually active woman childbearing potential must use effective birth control trial least two month follow trial . 9 . Men must willing avoid father new child receive therapy decitabine . 10 . Greater equal 18 year , upper age limit 11 . Individuals candidate hematopoietic stem cell transplantation meet study criterion may participate study receive intravenous decitabine combination arsenic trioxide Ascorbic acid treatment prior transplantation . 1 . Known central nervous system ( CNS ) leukemia . 2 . Previously receive great equal 5 cycle azacitidine ( Vidaza® , Pharmion Corp. , Boulder , CO ) decitabine ( Dacogen® , MGI Pharma Inc. Bloomington , MN ) . 3 . QTc &gt; 460 msec . 4 . Known suspected hypersensitivity decitabine , arsenic ascorbic acid . 5 . Receiving investigational agent within 30 day first dose study drug . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , congestive heart failure NYHA class 3 4 , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 7 . Known positive serology HIV . 8 . Had radiotherapy within 14 day prior study enrollment . 9 . Known presence hepatic tumor . 10 . &lt; 18 year age 11 . Exclude woman pregnant breast feeding . 12 . Known history glucose6phosphate deficiency ( G6PD ) . 13 . Currently take Class Ia Class III antiarrhythmic medication causally associate prolong QTc . 14 . Use aspirin platelet count &lt; 50,000/µl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>hypomethylating agent</keyword>
	<keyword>oxidative stress</keyword>
</DOC>